These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 16642707)
1. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way]. MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707 [No Abstract] [Full Text] [Related]
2. [A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive]. MMW Fortschr Med; 2005 May; 147(19):49. PubMed ID: 15940939 [No Abstract] [Full Text] [Related]
3. [Utilizing progress in modern antihypertensive therapy. Treating hypertension effectively from the beginning]. MMW Fortschr Med; 2005 May; 147(19):48. PubMed ID: 15940938 [No Abstract] [Full Text] [Related]
4. [J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)]. Yamamoto K; Hori M Nihon Rinsho; 2007 Apr; 65 Suppl 4():513-5. PubMed ID: 17511101 [No Abstract] [Full Text] [Related]
5. Losartan and hypertensive children. Another option for a small number of children. Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20939445 [No Abstract] [Full Text] [Related]
6. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico. Arredondo A; Burke TA; Carides GW; Lemus E; Querol J Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699 [TBL] [Abstract][Full Text] [Related]
7. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists]. Dominiak P; Zidek W MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703 [No Abstract] [Full Text] [Related]
9. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Devereux RB; Dahlöf B Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698 [TBL] [Abstract][Full Text] [Related]
13. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428 [TBL] [Abstract][Full Text] [Related]
14. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679 [TBL] [Abstract][Full Text] [Related]
15. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases]. Baumgart P MMW Fortschr Med; 2006 Mar; 148(11):57, 59-60. PubMed ID: 16612965 [No Abstract] [Full Text] [Related]
16. Renal and stroke protection in hypertensive patients at CV risk. Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036 [No Abstract] [Full Text] [Related]
17. Achieved vs initial blood pressure in predicting renal outcomes. Onuigbo MA Arch Intern Med; 2004 Jan; 164(2):223; author reply 223-4. PubMed ID: 14744850 [No Abstract] [Full Text] [Related]
18. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295 [TBL] [Abstract][Full Text] [Related]
19. [What are the consequences of the LIFE Study for general practice]. Zidek W MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704 [No Abstract] [Full Text] [Related]
20. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved]. Einecke D MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276 [No Abstract] [Full Text] [Related] [Next] [New Search]